About 30 results found for searched term "DS2" (0.034 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6789 | HDS 029 | Others |
| HDS 029 is a potent inhibitor of the ErbB receptor family. | ||
| M7762 | DS2 | Others |
| DS2 is a selective positive allosteric modulator of δ-GABAA receptors. | ||
| M9180 | Pyridostatin Trifluoroacetate Salt | DNA/RNA Synthesis |
| Pyridostatin TFA salt; PDS; CAS# 1085412-37-8(free base) | ||
| Pyridostatin Trifluoroacetate Salt is a G-quadruplexe stabilizer, with a Kd of 490 nM. | ||
| M9647 | Orludodstat (BAY-2402234) | DHODH |
| BAY-2402234 is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies, with an IC50 of 1.2 nM. | ||
| M9886 | DSPE-PEG-2K-Amine | Cell Transfection |
| DSPE-PEG(2000)-Amine; DSPE-PEG-Amine, MW 2000 ammonium; DSPE-PEG-NH2, MW 2000 ammonium | ||
| DSPE-PEG-2K-Amine is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE, used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents. | ||
| M9914 | Valemetostat | EZH2 |
| DS-3201；DS-3201b | ||
| Valemetostat (DS-3201, DS-3201b) is a first-in-class dual inhibitor targeting EZH1 and EZH2. It can be used in the study of adult T-cell leukemia/lymphoma. | ||
| M10122 | DSPE-mPEG2000 | Cell Transfection |
| Methyl-PEG2000-DSPE | ||
| DSPE-mPEG2000 is a phospholipid PEG conjμgate which has both hydrophilicity and hydrophobility. | ||
| M13351 | DSPE-PEG(2000)-MAL | Cell Transfection |
| DSPE-PEG(2000) Maleimide | ||
| DSPE-PEG-MAL is one of the reactive phospholipid PEG reagents that can react with sulfhydryl group (mercaptan, -SH). DSPE (1, 2-distearyl-Sn-glycerol 3-phosphate ethanolamine) is a highly hydrophobic saturated 18C phospholipid. | ||
| M13439 | Milademetan | Mdm2 |
| DS-3032 | ||
| Milademetan (DS-3032) is a specific, orally active MDM2 inhibitor for the study of acute myeloid leukemia and solid tumors. | ||
| M13553 | Milademetan tosylate hydrate | Mdm2 |
| DS-3032b; DS-3032 tosylate hydrate | ||
| Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. | ||
| M14691 | DS18561882 | Others |
| DS18561882 is a highly potent, isozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with an IC50 value of 0.0063 μM. | ||
| M21223 | DS96432529 | CDK |
| DS96432529 is a potent bone anabolic agent with oral activity and CDK8 inhibitory activity. | ||
| M21359 | DSPE-PEG-Biotin (MW 2000) | PROTAC Linker |
| DSPE-PEG-Biotin (MW 2000) is a PROTAC linker, which belongs to the PEG class. It can be used to synthesize PROTAC molecules. | ||
| M21487 | Valemetostat tosylate | Histone Methyltransferase |
| DS-3201 tosylate | ||
| Valemetostat tosylate (DS-3201 tosylate) is a first-in-class EZH1/2 inhibitor with IC50 < 10 nM. Valemetostat tosylate can be used in the study of relapsed and refractory peripheral T cell lymphoma. | ||
| M22180 | DSM265 | DHODH |
| DSM265 is a long-acting inhibitor of Plasmodium falciparum dihydroorotic acid dehydrogenase (PfDHODH) with an IC50 value of 8.9 nM. In addition, DSM265 inhibits the growth of Pf3D7 with an EC50 value of 4.3 nM. | ||
| M22197 | DSP2230 | Others |
| DSP2230 | ||
| M24699 | Vandortuzumab vedotin | ADC Linker |
| DSTP 3086S; RG 7450; MSTP2109A | ||
| Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M25505 | DSPE-PEG 2000 | Cell Transfection |
| DSPE-PEG 2000 is a PEG-lipid that can be used to form micelles as nanoparticles for drug delivery. | ||
| M27971 | DS-7423 | PI3K |
| DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. | ||
| M28955 | DS-1205b free base | TAM Receptor |
| DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. | ||
| M29232 | HPGDS inhibitor 2 | PGE synthase |
| HPGDS inhibitor 2 is a highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC50 of 9.9 nM. | ||
| M29300 | DS28120313 | Others |
| DS28120313 (compound 32) is an orally hepcidin production inhibitor with an IC50 of 0.093 μM. | ||
| M29567 | DS08210767 | Thyroid Hormone Receptor |
| DS08210767 is a highly potent, orally bioavailable PTHR1 antagonist with IC50 of 90 nM. | ||
| M29633 | DSM502 | DHODH |
| DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. | ||
| M29676 | Miclxin | Wnt/beta-catenin |
| DS37262926 | ||
| Miclxin (DS37262926) is a potent inhibitor of mutant β-catenin, involving in Wnt signaling pathway. Miclxin induces β-catenin-dependent apoptosis, leads to severe mitochondrial damage with the loss of mitochondrial membrane. Miclxin kills tumor via targeting to MIC60, a major components of the mitochondrial contact site and cristae organizing system (MICOS) complex. | ||
| M29711 | CMLD010509 | c-Myc |
| SDS-1-021 | ||
| CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism. | ||
| M29783 | DS20362725 | Estrogen Receptor |
| DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM). | ||
| M30450 | Mizagliflozin | SGLT |
| DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base | ||
| Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation. | ||
| M31186 | 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane | Others |
| TIPDSiCl2 | ||
| 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPDSiCl2,) is a silylation reagent that can be used to protect the 3'- and 5'-hydroxyl functions of ribonucleosides, to analyze Watson-Crick and Hoogstein base pairing in nucleotides, and to form ribavirin chemical delivery system. In addition, 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane is also a protecting group reagent for open-chain polyhydroxy compounds, which can be used to prepare cyclic bridging peptides. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
